Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer

NCT01309230 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT01309230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01309230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Lead sponsor
Gradalis, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 8, 2011
Completion date
February 2, 2022
Enrollment
39 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer